Haleon plc: Publication of
Annual Report and Form 20-F 2023
15
March 2024: Haleon plc (the
"Company") has today published its Annual Report and Form 20-F for
the year ended 31 December 2023 (the "Annual Report").
The Annual Report has been submitted
to the National Storage Mechanism and will shortly be available for
inspection at data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Company will also file the
Annual Report with the US Securities and Exchange Commission
today.
The Annual Report is publicly
available on the Company's website at www.haleon.com/investors/annual-report-2023.
In compliance with the Disclosure
Guidance and Transparency Rules, the Annual Report, as submitted to
the National Storage Mechanism, contains regulated information in
unedited full text and is available on the Company's website as
noted above.
Shareholders may request a hard copy
of the Annual Report, including the complete audited financial
statements of the Company. Requests should be directed to: Company
Secretariat, Haleon plc, Building 5, First Floor, The Heights,
Weybridge, KT13 0NY, United Kingdom or to corporate.secretariat@haleon.com.
The Company's Annual General Meeting
("AGM") will take place on 8 May 2024. The Notice of AGM will be
published and distributed to shareholders in due course.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE / NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.